However, NGS technology may be a good strategy to test for the four most important alterations in myeloproliferative neoplasms (namely JAK2, CALR, MPL mutations and BCR-ABL1 fusions), together with biomarkers diagnostic of myeloid/lymphoid neoplasms with rearrangements of PDGFRA, PDGFRB, FGFR1, and PCM1-JAK2 or inherent to myelodysplastic/myeloproliferative neoplasms (MDS/MPN) diseases. This evidence concerns the gene JAK2 and myeloproliferative disorder.